Taipei, Taiwan, December 22, 2017 6:00pm – OBI Pharma, Inc. (TPEx:4174), a Taiwan biopharma company specializing in the development of novel first-in-class cancer therapeutics that uniquely target Globo Series (including Globo H) and AKR1C3, announced that it will participate at the 36th J.P. Morgan Annual Healthcare Conference.
The conference is being held on January 8-11, 2018, in San Francisco. J.P. Morgan will be organizing OBI Pharma one-on-one meetings with investors. Investors wishing to attend can also contact our IR team at firstname.lastname@example.org.
About OBI Pharma
OBI Pharma, Inc. is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (including Globo H), AKR1C3, and other promising targets.
The company’s novel first-in-class immuno-oncology portfolio against Globo Series includes: Adagloxad Simolenin (formerly OBI-822), a Globo Series active immunotherapy vaccine; OBI-888 (Globo H mAb) and OBI-999 (Globo H ADC). The company’s novel first-in-class AKR1C3 targeted therapy is OBI-3424 (small-molecule prodrug) that selectively releases a potent DNA alkylating agent in the presence of the aldo-keto reductase 1c3 (AKR1C3) enzyme. Additional information can be found at www.obipharma.com.
Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma’s reports and presentations, including OBI Pharma’s filings with the Taiwan Securities and Futures Bureau.
OBI Pharma, Inc.
+886 (2) 2786-6589